Maryland Patent of the Month – July 2024
Cartesian Therapeutics Inc. is pioneering a novel approach to combat BCMA-related conditions with advanced chimeric antigen receptor (CAR) T cell therapy. BCMA, a crucial receptor in B cell maturation, is implicated in various cancers and autoimmune diseases. Traditional treatments for these conditions often involve systemic steroids or immunosuppressants, leading to significant side effects and long-term toxicity.
The innovative therapy by Cartesian Therapeutics involves genetically modifying T cells to express CARs that specifically target BCMA, offering a highly targeted and effective treatment. The new CAR constructs feature enhanced binding properties and improved expression, resulting in superior tumor-killing capabilities. These improvements stem from modifications in the CAR’s complementarity-determining regions (CDRs), transmembrane domains, and cytoplasmic domains, which collectively optimize the CAR T cells’ performance.
In preclinical studies, these CAR T cells demonstrated remarkable efficacy in killing multiple myeloma cells both in vitro and in vivo. By enhancing the binding affinity and stability of the CARs, Cartesian Therapeutics has addressed common challenges in CAR T cell therapy, such as suboptimal target engagement and inflammatory side effects.
This breakthrough promises a significant advancement in the treatment of hematological cancers like multiple myeloma, Hodgkin’s lymphoma, and various leukemias. Furthermore, it offers hope for patients suffering from autoimmune disorders and severe allergies, potentially reducing the need for chronic immunosuppressive therapies.
The potential of Cartesian Therapeutics’ CAR T cell therapy extends beyond cancer treatment, offering a versatile platform for addressing a range of BCMA-related diseases. By leveraging cutting-edge genetic engineering techniques, Cartesian Therapeutics is at the forefront of developing personalized, highly effective therapies that could transform patient outcomes and improve quality of life for those affected by these challenging conditions.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
